Vyant Bio Announces Investor Conference Call and Webcast

CHERRY HILL, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reimagining drug discovery for neurodevelopmental disorders and complex neurodegeneratives. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scale biology and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first six months ended June 30, 2022 on Monday, August 15, 2022. Vyant Bio will host an investor conference call and webcast on Monday August 15, 2022. at 4:30 p.m. ET.

Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer, and Robert Fremeau, PhD, Chief Scientific Officer, of Vyant Bio will provide an update on business, scientific and financial progress made during the second quarter and first half of 2022 Management will also respond to public questions submitted in advance only. Investors may submit written questions via email to: [email protected]

Event: Vyant Bio Investor Q2 and H1 2022 Conference Call and Webcast
Date: Monday, August 15, 2022
Time: 4:30 p.m. ET
Compose: Toll free: 1.844.369.8770 Conference number: 46372
Webcast: https://www.webcaster4.com/Webcast/Page/2756/46372

The event will be recorded and available for replay. Details of the conference call and webcast are also included in the Investors section of Vyant Bio’s corporate website at www.vyantbio.com.


Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapies. Vyant Bio has built a therapeutic platform aimed at treating neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett syndrome (“Rett”), CDKL5 deficiency disorders (“CDD”) and Parkinson’s disease. Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to reduce candidate screening risks, with the aim of improving potential efficacy drugs discovered earlier in the development cycle. Vyant Bio management believes that drug discovery must gradually shift to more efficient methods, as widely used models for predicting safe and effective drugs have underperformed, as evidenced by the significant time and cost to bring new medications to patients. By combining sophisticated data science capabilities with highly functional disease models derived from human cells, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to data assimilation. that supports decision-making iteratively throughout the discovery phase of drug development. to identify both new and repurposed CNS therapeutic candidates.

For more information, please visit or follow Vyant Bio on:
The Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements relating to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the effectiveness of our screening and drug discovery process, and the potential for our services, future revenues or growth in this press release constitute forward-looking statements. All statements that are not historical facts (including, but not limited to, statements containing words such as “will”, “believe”, “plan”, “anticipate”, “expect” and “esteem”) must also be taken into account. be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapting to the global coronavirus pandemic, raising capital to meet our liquidity needs, and other risks discussed in Vyant Bio, Inc.’s Form 10-K for the year ended 31 December 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

Investor contacts:
Skyline Business Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
Email: [email protected]


Michael P. Boser